NICOLA HANANIA to Dyspnea
This is a "connection" page, showing publications NICOLA HANANIA has written about Dyspnea.
Connection Strength
2.490
-
Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
Score: 0.797
-
Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019; 14:1127-1138.
Score: 0.568
-
The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. Respir Med. 2022 06; 197:106850.
Score: 0.173
-
Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
Score: 0.171
-
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
Score: 0.122
-
Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016 Apr; 149(4):927-35.
Score: 0.112
-
Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
Score: 0.093
-
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
Score: 0.092
-
Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
Score: 0.071
-
A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA. 2025 06 24; 333(24):2164-2175.
Score: 0.054
-
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 May; 241:108015.
Score: 0.053
-
Early Evidence of Chronic Obstructive Pulmonary Disease Obscured by Race-Specific Prediction Equations. Am J Respir Crit Care Med. 2024 01 01; 209(1):59-69.
Score: 0.049
-
Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
Score: 0.045
-
Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
Score: 0.029
-
Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
Score: 0.028
-
Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
Score: 0.018
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
Score: 0.015